Cancer screening rates low

Article

The percentage of Americans getting screened for cancer is below national targets with lower rates in the Asian and Hispanic populations, says the Centers for Disease Control and Prevention (CDC) and the National Cancer Institute in a study released last Friday. The study revealed that in 2010 breast cancer screening rates were 72.4 percent, which is below the target of 81 percent set by Healthy People 2020, a government initiative to set benchmarks to measure the impact of prevention activities. Cervical cancer screening was at 83 percent compared with the benchmark of 93 percent; and colorectal cancer screening was at 58.6 percent lower than the target of 70.5 percent. According to the report, screening rates in the Asian population were "significantly lower" at 64.1 percent for breast cancer, 75.4 percent for cervical cancer and 46.9 percent for colorectal cancer. Hispanics were less likely to be screened for cervical cancer (78.7 percent) and colorectal cancer (46.5 percent) compared with non-Hispanics at 83.8 percent and 59.9 percent, respectively. In a statement accompanying the study, lead author Sallyann Coleman King, MD, said, "It is troubling to see that not all Americans are getting the recommended cancer screenings and that disparities continue to persist for certain populations. Screening can find breast, cervical, and colorectal cancers at an early stage when treatment is more effective." King, who is also an epidemic intelligence service officer in the CDC's division of cancer prevention, added, "We must continue to monitor cancer screening rates to improve the health of all Americans." While financial costs may be a barrier to some in obtaining screening, the report also notes programs that can help. The CDC's National Breast and Cervical Cancer Early Detection Program provides access to free or low-cost screening and diagnostic services to underserved women across the country. The CDC's Colorectal Cancer Control Program offers access to screening to underserved men and women in 25 states. In addition, reducing financial barriers to preventive care is an aim of the Affordable Care Act. Under the act, breast, cervical and colorectal cancer screening is covered free under Medicare and new health insurance plans.

Related Videos
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Yuliya P.L Linhares, MD, an expert on CLL
Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL
Image of a man with a beard.
Image of a man with gray facial hair and a navy blue suit with a light orange tie.
Image of a woman with black hair.
Related Content